Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 16, 2007 - Issue 11
Submit an article Journal homepage
77
Views
5
CrossRef citations to date
0
Altmetric
Review

Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia

Mohamed A Kharfan-Dabaja Assistant Professor of Medicine, H. Lee Moffitt Cancer Center and Research Institute, Division of Blood and Marrow Transplantation, 12902 Magnolia Drive, BMT-WCB, Tampa, FL 33612, USA +1 813 745 8248; +1 813 979 8468; [email protected]
, MD FACP,
Rabih Fahed Clinical Research Fellow, Tulane University School of Medicine, 1430 Tulane Avenue, SL-78, New Orleans, LA 70112, USA
, MD,
Mohamad Hussein Professor of Medicine, Clinical Director (Malignant Hematology Division), University of South Florida, H. Lee Moffitt Cancer Center & Research Institute, Division of Hematologic Malignancies, 12902 Magnolia Drive, SRB-4, Tampa, FL 33612, USA
, MD &
Edgardo S Santos Assistant Scientific Director (Office of Clinical Research), Associate Director (Hematology-Oncology Fellowship Program), Co-Leader (Clinical Research-Louisiana Cancer Research Consortium), Tulane University School of Medicine, 1430 Tulane Avenue, SL-78, New Orleans, LA 70112, USA
, MD FACP
Pages 1799-1815 | Published online: 30 Oct 2007

Bibliography

  • SAWITSKY A, RAI KR, GLIDEWELL O, SILVER RT: Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood (1977) 50(6):1049-1059.
  • MONTSERRAT E, ALCALA A, PARODY R et al.: Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer (1985) 56(10):2369-2375.
  • RAPHAEL B, ANDERSEN JW, SILBER R et al.: Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern cooperative oncology group randomized clinical trial. J. Clin. Oncol. (1991) 9(5):770-776.
  • KEATING MJ, O'BRIEN S, ALBITAR M et al.: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. (2005) 23(18):4079-4088.
  • WIERDA W, O'BRIEN S, WEN S et al.: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. (2005) 23(18):4070-4078.
  • WIERDA W, O'BRIEN S, FADERL S et al.: A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer (2006) 106(2):337-345.
  • RAI KR, PETERSON BL, APPELBAUM FR et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. (2000) 343(24):1750-1757.
  • TREUMANN A, LIFELY MR, SCHNEIDER P et al.: Primary structure of CD52. J. Biol. Chem. (1995) 270(11):6088-6099.
  • HALE G, BRIGHT S, CHUMBLEY G et al.: Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood (1983) 62(4):873-882.
  • ROBAK T: Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk. Lymphoma (2004) 45(2):205-219.
  • O'BRIEN SM, KANTARJIAN HM, THOMAS DA et al.: Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer (2003) 98(12):2657-2663.
  • MORETON P, KENNEDY B, LUCAS G et al.: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J. Clin. Oncol. (2005) 23(13):2971-2979.
  • MONTILLO M, TEDESCHI A, MIQUELEIZ S et al.: Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J. Clin. Oncol. (2006) 24(15):2337-2342.
  • O'BRIEN S: Practical applications of measuring and monitoring MRD in patients with CLL. Clin. Adv. Hematol. Oncol. (2006) 4(5):8-9.
  • MONTILLO M, SCHINKOETHE T, ELTER T: Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. Cancer Invest. (2005) 23(6):488-496.
  • RAWSTRON AC, KENNEDY B, EVANS PA et al.: Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood (2001) 98(1):29-35.
  • PFITZNER T, REISER M, BARTH S et al.: Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Ann. Hematol. (2002) 81(5):258-266.
  • RAWSTRON AC, VILLAMOR N, RITGEN M et al.: International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia (2007) 21(5):1-9.
  • HALE G, DYER MJ, CLARK MR et al.: Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody Campath-1H. Lancet (1988) 2(8625):1394-1399.
  • DYER MJ, HALE G, HAYHOE FG, WALDMANN H: Effects of Campath-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood (1989) 73(6):1431-1439.
  • BINDON CI, HALE G, WALDMANN H: Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur. J. Immunol. (1988) 18(10):1507-1514.
  • KARLSSON C, HANSSON L, CELSING F, LUNDIN J: Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia (2007) 21(3):511-514.
  • ÖSTERBORG A, DYER MJS, BUNJES D et al.: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. (1997) 15(4):1567-1574.
  • KEATING MJ, FLINN I, JAIN V et al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who failed fludarabine: results of a large international study. Blood (2002) 99(10):3554-3561.
  • RAI K, SAWITSKY, KRONKITE EP et al.: Clinical staging of chronic lymphocytic leukemia. Blood (1975) 46(2):219-234.
  • RAI KR, FRETER CE, MERCIER RJ et al.: Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J. Clin. Oncol. (2002) 20(18):3891-3897.
  • MCCUNE SL, GOCKERMAN JP, MOORE JO et al.: Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocyic leukemia. Leuk. Lymphoma (2002) 43(5):1007-1011.
  • LAURENTI L, PICCIONI P, TARNANI N et al.: Low-dose alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience. Haematologica (2005) 90(8):1143-1145.
  • BOWEN AL, ZOMAS A, EMMETT E et al.: Subcutaneous Campath-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br. J. Haematol. (1997) 96(3):617-619.
  • FERRAJOLI A, O'BRIEN SM, CORTES JE et al.: Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer (2003) 98(4):773-778.
  • FIEGL M, FALKNER A, HOPFINGER G et al.: Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer (2006) 107(10):2408-2416.
  • KENNEDY B, RAWSTRON A, CARTER C et al.: Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood (2002) 99(6):2245-2247.
  • ELTER T, BORCHMANN P, SCHULZ H et al.: Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a Phase II trial. J. Clin. Oncol. (2005) 23(28):7024-7031.
  • FADERL S, THOMAS DA, O'BRIEN S et al.: Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood (2003) 101(9):3413-3415.
  • NABHAN C, PATTON D, GORDON LI et al.: A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk. Lymphoma (2004) 45(11):2269-2273.
  • DOHNER H, STILGENBAUER S, BENNER A et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. (2000) 343(26):1910-1916.
  • FAIS F, GHIOTTO F, HASHIMOTO S et al.: Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J. Clin. Invest. (1998) 102(8):1515-1525.
  • CHIORAZZI N, RAI KR, FERRARINI M: Chronic lymphocytic leukemia. N. Engl. J. Med. (2005) 352(8):804-815.
  • IBRAHIM S, KEATING M, DO KA et al.: CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood (2001) 98(1):181-186.
  • RASSENTI LZ, HUYNH L, TOY TL et al.: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N. Engl. J. Med. (2004) 351(9):893-901.
  • DOHNER H, FISCHER K, BENTZ M et al.: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood (1995) 85(6):1580-1589.
  • LIN K, SHERRINGTON PD, DENNIS M et al.: Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood (2002) 100(4):1404-1409.
  • EL ROUBY S, THOMAS A, COSTIN D et al.: p53 mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood (1993) 82(11):3452-3459.
  • STURM I, BOSANQUET AG, HERMANN S et al.: Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Diff. (2003) 10(4):477-484.
  • BYRD JC, GRIBBEN JG, PETERSON BL et al.: Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for a risk-adapted therapy. J. Clin. Oncol. (2006) 24(3):437-443.
  • LOZANSKI G, HEEREMA NA, FLINN IW et al.: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood (2004) 103(9):3278-3281.
  • OSUJI NC, DEL GIUDICE I, MATUTES E et al.: The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica (2005) 90(10):1435-1436.
  • STILGENBAUER S, DOHNER H: Campath-1H-iinduced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N. Engl. J. Med. (2002) 347(6):452-453.
  • STILGENBAUER S, WINKLER D, KROBER A et al.: Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL: interim analysis of the CLL2h study of the German CLL study group (GCLLSG). Blood (2004) 104:(Abstract 478).
  • ÖSTERBORG A, FASSAS AS, ANAGNOSTOPOULOS A, DYER MJS: Humanized CD52 monoclonal antibody Campath-1H as first line treatment in chronic lymphocytic leukaemia. Br. J. Haematol. (1996) 93(1):151-153.
  • LUNDIN J, KIMBY E, BJÖRKHOLM M et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood (2002) 100(3):768-773.
  • HILLMEN P, SKOTNICKI A, ROBAK T et al.: Preliminary Phase III efficacy and safety of alemtuzumab versus chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL). J. Clin. Oncol. (2006) 24(18S):(Abstract 6511).
  • DMOSZYNSKA A, FETNI R, WANG Y et al.: Cytogenetic correlation with efficacy on alemtuzumab (CAM) versus chlorambucil (CHLO) as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL). J. Clin. Oncol. (2006) 24(18S):(Abstract 6601).
  • MONTILLO M, CAFRO AM, TEDESCHI A et al.: Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica (2002) 87(7):695-700.
  • WENDTNER C-M, RITGEN M, SCHWEIGHOFER CD et al.: Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter Phase III trial of the German CLL study group (GCLLSG). Leukemia (2004) 18(6):1093-1101.
  • CARELLA AM, BELTRAMI G, SCALZULLI PR et al.: Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplant. (2004) 33(1):131-132.
  • TEDESCHI A, CAIROLI R, MONTILLO M et al.: Feasibility of autologous stem cell transplantation (ASCT) in chronic lymphocytic leukemia (CLL) patients treated with sequential fludarabine and Campath-1H. Blood (2004) 104(11):A520 (Abstract 1879).
  • MONTSERRAT E, MORENO C, ESTEVE J et al.: How I treat refractory CLL. Blood (2006) 107(4):1276-1283.
  • MICHALLET M, ARCHIMBAUD E, BANDINI G et al.: HLA-identical sibling bone marrow transplants for chronic lymphocytic leukaemia. Ann. Intern. Med. (1996) 124(3):311-315.
  • MICHALLET M, MICHALLET AS, LE QH et al.: Conventional HLA-identical sibling bone marrow transplantation is able to cure chronic lymphocytic leukemia. Blood (2003) 102:A474 (Abstract 1729).
  • TOZE CL, GALAL A, BARNETT MJ et al.: Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant. (2005) 36(9):825-830.
  • DELGADO J, THOMSON K, RUSSELL N et al.: Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British society of blood and marrow transplantation study. Blood (2006) 107(4):1724-1730.
  • KOTTARIDIS PD, MILLIGAN DW, CHOPRA R et al.: In vivo Campath-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 96(7):2419-2425.
  • CHAKRAVERTY R, PEGGS K, CHOPRA R et al.: Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood (2002) 99(3):1071-1078.
  • PEREZ-SIMON JA, KOTTARIDIS P, MARTINO R et al.: Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood (2002) 100(9):3121-3127.
  • GRILLO-LOPEZ AJ, WHITE CA, VARNS C et al.: Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin. Oncol. (1999) 26(5 Suppl. 14):66-73.
  • NGUYEN DT, AMESS JA, DOUGHTY H et al.: IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur. J. Haematol. (1999) 62(2):76-82.
  • MALONEY DG, GRILLO-LOPEZ AJ, WHITE CA et al.: IDECC2B8 (rituximab) anti-CD20- monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 90(6):2188-2195.
  • PIRO LD, WHITE CA, GRILLO-LOPEZ AJ et al.: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. (1999) 10(6):655-661.
  • O'BRIEN SM, KANTARJIAN H, THOMAS DA et al.: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. (2001) 19(8):2165-2170.
  • BYRD JC, MURPHY T, HOWARD RS et al.: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. (2001) 19(8):2153-2164.
  • HUHN D, VON SCHILLING C, WILHELM M et al.: Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood (2001) 98(5):1326-1331.
  • HAINSWORTH JD, LITCHY S, BARTON JH et al.: Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a Phase II trial of the Minnie Pearl cancer research network. J. Clin. Oncol. (2003) 21(9):1746-1751.
  • HAINSWORTH JD, LITCHY S, BURRIS HA III et al.: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J. Clin. Oncol. (2002) 20(20):4261-4267.
  • MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. (1998) 16(8):2825-2833.
  • BERINSTEIN N, GRILLO-LOPEZ A, WHITE CA et al.: Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. (1998) 9(9):995-1001.
  • ITALA M, GEISLER CH, KIMBY E et al.: Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur. J. Haematol. (2002) 69(3):129-134.
  • FORAN JM, ROHATINER AZ, CUNNINGHAM D et al.: European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J. Clin. Oncol. (2000) 18(2):317-324.
  • SCHULZ H, KLEIN SK, REHWALD U et al.: Phase II study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukaemia. Blood (2002) 100(9):3115-3120.
  • SAVAGE DG, COHEN, HESDORFFER CS et al.: Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukaemia. Leuk. Lymphoma (2003) 44(3):477-481.
  • BYRD JC, PETERSON B, MORRISON VA et al.: Randomized Phase II study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic,untreated patients with B-cell chronic lymphocytic leukemia: results from cancer and leukemia group B 9712 (CALGB 9712). Blood (2003) 101(1):6-14.
  • BYRD JC, RAI K, PETERSON BL et al.: The addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood (2005) 105(1):49-53.
  • KAY NE, GEYER SM, CALL T et al.: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood (2007) 109(2):405-411.
  • WIERDA WG, O'BRIEN S, FERRAJOLI A et al.: Salvage therapy with combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) for heavily pre-treated patients with CLL. Blood (2005) 106(11):(Abstract 719).
  • WIERDA W, O'BRIEN S, FADERL S et al.: Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for heavily pretreated patients with CLL. Blood (2006) 108(11):(Abstract 31).
  • LAMANNA N, KALAYCIO M, MASLAK P et al.: Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J. Clin. Oncol. (2006) 24(10):1575-1581.
  • CHANAN-KHAN A, MILLER KC, MUSIAL L et al.: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a Phase II study. J. Clin. Oncol. (2006) 24(34):5343-5349.
  • CHANAN-KHAN A, MILLER K, MUSIAL L et al.: Clinical efficacy of lenalidomide (Revlimid) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): updated results of a Phase II clinical trial. Blood (2006) 108(11):(Abstract 306).
  • COIFFIER B, TILLY H, PEDERSEN LM et al.: HuMax CD20 fully human monoclonal antibody in chronic lymphocytic leukemia: early results from an ongoing Phase I/II clinical trial. Blood (2005) 106(11):A135 (Abstract 448).
  • BYRD J, O'BRIEN S, FLINN I et al.: Interim results from a Phase I of lumiliximab (IDEC-152, anti-CD23 antibody) therapy for relapsed or refractory CLL. Blood (2003) 102(11):A74 (Abstract 248).
  • BYRD JC, FLINN IW, KHAN KD et al.: Pharmacokinetics and pharmacodynamics from a first-in-human Phase I dose escalation study with antagonist anti-CD40 antibody, HCD122 (formerly CHIR-12.12), in patients with relapsed and refractory chronic lymphocytic leukemia. Blood (2006) 108(11):(Abstract 2837).
  • GOWDA AC, ZHAO XB, CHENEY C et al.: Humanized anti CD-40 antibody SGN-40 effectively induces cytotoxicity against chronic lymphocytic leukemia (CLL) cells through antibody mediated cytotoxicity and demonstrates modest biologic evidence of CD40 activation. Blood (2005) 106(11):A832 (Abstract 2966).
  • ADVANI RH, FURMAN RR, ROSENBLATT JD et al.: A Phase I study of humanized anti-CD40 immunotherapy with SGN-40 in non-Hodgkin's lymphoma. Blood (2005) 106(11):A433 (Abstract 1504).
  • NAGY ZA, HUBNER B, LOHNING C et al.: Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat. Med. (2002) 8(8):801-807.
  • CARLO-STELLA C, DI NICOLA M, TURCO C et al.: In vitro and in vivo anti-lymphoma activity of the anti-HLA-DR monoclonal antibody 1D09C3. Blood (2004) 104(11):(Abstract 3285).
  • GIANNI AM, CARLO-STELLA C, GUIDETTI A et al.: Two Phase I open-label studies of the fully human HLA-DR-specific IgG4 monoclonal antibody 1D09C3 in patients with relapsed and/or refractory B-cell lymphoproliferative neoplasias on a weekly and bi-weekly dosing scheme. Blood (2006) 108(11):(Abstract 2730).
  • LEONARD JP, COLEMAN M, KETAS JC et al.: Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results. Clin. Cancer Res. (2004) 10(16):5327-5334.
  • LEONARD JP, COLEMAN M, KETAS J et al.: Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J. Clin. Oncol. (2005) 23(22):5044-5051.
  • LANGER CJ, NATALE RB: The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors. Semin. Oncol. (2005) 32(6 Suppl. 10):S23-S29.
  • MOLICA S, VITELLI G, LEVATO D, RICCIOTTI A, DIGIESI G: Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. Br. J. Cancer (2002) 86(1):31-35.
  • KAY NE, BONE ND, TSCHUMPER RC et al.: B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia (2002) 16(5):911-919.
  • KARP JE, GOJO I, GOCKE CD et al.: Timed sequential therapy (TST) of relapsed and refractory adult acute myelogenous leukemia (AML) with the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab. Blood (2002) 100:A198 (Abstract 744).
  • LIU NS, KEATING MJ, ALBITAR M et al.: Yttrium-90 ibritumomab tiuxetan for minimal residual disease in CLL. Blood (2003) 102(11):(Abstract 2498).
  • PRESS OW, EARY JF, APPELBAUM FR et al.: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. (1993) 329:1219-1224.
  • VOSE JM, BIERMAN PJ, ENKE C et al.: Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. (2005) 23:461-467.
  • O'BRIEN SM, KEATING MJ, MOCARSKI ES: Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin. Lymphoma Myeloma (2006) 7(2):125-130.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.